Colorectal Cancer Clinical Trial
Official title:
Phase 2 Prospective Randomized Double Blind Trial Comparing Metastasectomy Plus Sulindac Versus Metastasectomy Alone in Patients With Stage IV Colorectal Cancer
Background:
- Some types of inflammation may increase the risk of cancers in the intestinal track.
Because of this possibility, anti-inflammatory drugs may be able to prevent tumor growth and
spread. One such drug, sulindac, may be helpful to study. Researchers want to see if people
who are having surgery to remove intestinal tumors from advanced colorectal cancer will
benefit from sulindac. It will be tested against a placebo.
Objectives:
- To see if sulindac can improve treatment outcomes in people who are having surgery for
advanced colorectal cancer.
Eligibility:
- Individuals at least 18 years of age who are having surgery for advanced colorectal
cancer.
Design:
- Participants will be screened with a physical exam and medical history. Blood samples
will be collected. Imaging studies and heart and lung function tests may also be given.
- Participants will be separated into two groups. One group will take sulindac. The other
will take a placebo.
- Participants will take sulindac or placebo twice daily from about 2 to 3 weeks before
the scheduled surgery. Seven days before the surgery, they will stop taking the pills.
- Participants will have surgery to remove their tumors. The surgery will also remove
affected organ tissue.
- Participants will start to take the pills again once they have recovered from surgery.
They will continue taking the sulindac or placebo twice a day for 3 years, or for as
long as the tumors do not return.
- Despite strong evidence for a causative role of inflammatory mediators in intestinal
cancer, the underlying mechanisms remain obscure. Established evidence indicates
activation of the Wnt/beta-catenin pathway is an early step in the malignant
transformation of colorectal adenomas with persistent activation in 90% of colorectal
cancers. Activation of this pathway ultimately effects transcription of the S100A4
gene.
- S100A4 transcript serum levels have been shown to correlate with risk of recurrence in
colorectal cancer and patients with systemic metastases are found to have increased
S100A4 transcript expression.
- S100A4 may be a novel prognostic biomarker in colorectal cancer.
- Cyclooxygenase-2 is a key enzyme involved in the inflammatory response and is a key
target of molecular chemoprevention in colorectal adenoma prevention trials.
- Recent studies demonstrate mitigation of Wnt/beta-catenin signaling by COX-2 inhibition
via administration of the non-steroidal anti-inflammatory drug (NSAID) sulindac using
in vitro and in vivo animal models.
- We hypothesize that sulindac administration will abrogate Wnt/beta-catenin mediated
signaling and thus decrease S100A4 activity in patients with colorectal metastases.
- We propose to define the benefit of sulindac administration to patients with colorectal
metastases following resection and validate the use of circulating S100A4 transcripts
as a novel biomarker for disease recurrence.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |